Results 151 to 160 of about 60,584 (224)

[Corrigendum] ND‑09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR‑ABL signaling. [PDF]

Oncol Rep
Liu YH, Zhu M, Lei PP, Pan XY, Ma WN.
europepmc   +1 more source

3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib. [PDF]

Pharmaceuticals (Basel)
Cabezas D, Delgado T, Sepúlveda G, Krňávková P, Vojáčková V, Kryštof V, Strnad M, Silva NI, Echeverría J, Espinosa-Bustos C, Mellado G, Luo J, Mella J, Salas CO.   +13 more
europepmc   +1 more source

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia. [PDF]

Cancer Res
Luo Z, Lin C, Yu C, Yuan C, Wu W, Xu X, Sun R, Jia Y, Wang Y, Shen J, Wang D, Wang S, Jiang H, Jiang B, Yang X, Xie C.   +15 more
europepmc   +1 more source

CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells. [PDF]

Cell Death Discov
Khamidullina AI, Yastrebova MA, Bruter AV, Nuzhina JV, Vorobyeva NE, Khrustaleva AM, Varlamova EA, Tyakht AV, Abramenko IE, Ivanova ES, Zamkova MA, Li J, Lim CU, Chen M, Broude EV, Roninson IB, Shtil AA, Tatarskiy VV.   +17 more
europepmc   +1 more source

Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa. [PDF]

EJHaem
Ayalew ZS, Azibte GT, Tadesse F, Legesse BA, Kiflu ZG, Weldeamanuel MT, Tsige KA, Molla BA, Ejigu AM.   +8 more
europepmc   +1 more source

Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. [PDF]

Mediterr J Hematol Infect Dis
Paciaroni K, Campagna S, Villiva N, Maffini E, Celesti F, Tordi A, Lombardi M, Dragonetti G, di Toritto TC.   +8 more
europepmc   +1 more source

The Emergence of a Novel Insertional Mutation in the BCR::ABL/p210 Oncogene in B-Cell Acute Lymphoblastic Leukemia (B-ALL) Correlates with the Development of Resistance to Several Tyrosine Kinase Inhibitors. [PDF]

Acta Naturae
Bogdanov KV, Kudryavtseva ES, Lobacheva YN, Merzlikina OV, Mirolyubova YV, Vlasik RA, Badaev RS, Lomaia EG.   +7 more
europepmc   +1 more source

Mebendazole effectively overcomes imatinib resistance by dual-targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells. [PDF]

Korean J Physiol Pharmacol
Yang L, Du Z, Peng Y, Zhang W, Feng W, Yuan Y.   +5 more
europepmc   +1 more source

Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN. [PDF]

J Nanobiotechnology
Sun Y, Wang Y, Liu C, Huang Y, Long Q, Ju C, Zhang C, Chen Y.   +7 more
europepmc   +1 more source